United Therapeutics CorpUTHR
Price$541.89Intrinsic value$398.2527% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.2B+9.6% YoYTTM through 30 Jun 2026
Net Income $1.3B+9.7% YoYTTM through 30 Jun 2026
Free Cash Flow $1.1BTTM through 30 Jun 2026

Margins

Current
Gross Margin82.9%
EBITDA Margin47.3%
Operating Margin41.7%
Net Margin41.6%

Returns

20.3%ROE
12.6%ROA
28.5%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.79x
Net Debt-$3.5Bnet cash position
Cash & Equivalents$1.8B

Quality Metrics

Altman Z-Score18.95
Piotroski F-Score7 / 9
FCF Margin34.6%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $3.2B
Diluted EPS$27.91TTM
'19'20'21'22'23'24'25
FY2025: $27.86

Dividend

No dividend

Capital Allocation

R&D Spend$551.5M
Capex Intensity18.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.